Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Amgen Boosts Earnings Outlook After Strong Q2

Guavy AI Editorial Team
Instruments
AMGN
Share

Amgen Inc., known for its biopharmaceutical products, has revised its profit and revenue guidance for 2026. The company reported Q2 financial results that beat expectations on both lines.

The biopharma now sees full-year non-GAAP EPS of $22.30-$23.50, up from a previous forecast of $21.70-$23.10. This increase is in line with the consensus estimate of $22.35.

Amgen also raised its revenue guidance for 2026, projecting it to be between $38B-$39.4B, up from a previous range of $37.1B-$38.5B. The consensus revenue estimate is $37.73B.

More on Stocks

Stocks just now

Delta Flight Diverted from Iceland to Lisbon After Mechanical Issue

Stocks just now

Caterpillar Sees Record Sales on AI-Driven Demand

Stocks 2m ago

Amgen Revenue Jumps 10%, Raises Full-Year Outlook Amid Key Medicine Growth

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Real-time market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy